Publications by authors named "C Verstuyft"
Mavacamten, the first drug in the class of β-cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in pharmacokinetics parameters, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 poor metabolizers have increased exposure and are at increased risk of reduced cardiac hypercontractility.
View Article and Find Full Text PDFBackground And Aims: Statin-associated muscle symptoms (SAMS) are a major cause of treatment discontinuation. Clinical Pharmacogenetics Implementation Consortium (CPIC) recommend dose adjustment for statin treatment according to known SLCO1B1 genotype to reduce SAMS. We hypothesized that the association between SLCO1B1 genotype and SAMS is misestimated because of publication bias.
View Article and Find Full Text PDFArticle Synopsis
- * In the study, 20 volunteers ingested caffeine through different sources while their blood was collected via DBS to monitor pharmacokinetics and assess how genetics affect caffeine metabolism.
- * Results showed feasibility in collecting pharmacokinetic data in-flight, revealing varying metabolism rates among participants, particularly influenced by gender and contraceptive use, with significant differences observed in caffeine absorption based on the consumed source.
Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Genetic factors influence the effect of its main treatment option, antidepressant drugs (ATD). The GRIK4 rs1954787(T>C) genetic polymorphism was associated with response following 1-3 months of ATD treatment in some studies, but not others.
View Article and Find Full Text PDF